Prosecution Insights
Last updated: November 04, 2026
Application No. 17/601,147

AGROCHEMICAL COMPOSITION WITH ENHANCED EFFICACY

Final Rejection §102§103
Filed
Oct 04, 2021
Priority
Apr 05, 2019 — JP 2019-072794 +1 more
Examiner
PALLAY, MICHAEL B
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mitsui Chemicals Agro Inc.
OA Round
6 (Final)
56%
Grant Probability
Moderate
7-8
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
417 granted / 746 resolved
-4.1% vs TC avg
Strong +34% interview lift
Without
With
+33.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
74 currently pending
Career history
803
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
47.6%
+7.6% vs TC avg
§102
12.0%
-28.0% vs TC avg
§112
24.7%
-15.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 746 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 13 April 2026 has been entered. Status Applicant’s response dated 13 April 2026 to the previous Office action dated 13 January 2026 is acknowledged. Pursuant to amendments therein, claims 1, 5, 8-9, and 12-20 are pending in the application. The rejection under 35 U.S.C. 112 made in the previous Office action is/are withdrawn in view of applicant’s claim amendments. The rejection under 35 U.S.C. 102 made in the previous Office action is/are withdrawn in view of applicant’s claim amendments, but a new (modified) rejection under 35 U.S.C. 102 is made herein in view of applicant’s claim amendments. The rejection under 35 U.S.C. 103 made in the previous Office action is withdrawn in view of applicant’s claim amendments, but a new rejection under 35 U.S.C. 103 is made herein in view of applicant’s claim amendments. Response to Arguments Applicant's arguments filed 13 April 2026 have been fully considered but they are not persuasive with respect to the current prior art rejections. Applicant argues that Yang et al. (of record) requires alginic acid but claims 16-17 and 19-20 exclude alginic acid (remarks pages 8-9). In response, alginic acid is a binder, thickener, and bulking agent, which are not excluded from the claims (see, e.g., instant specification at paragraph [0078] of published application). Applicant’s arguments regarding Burkhart et al. (of record) requiring a weight ratio excluded by the current claims is persuasive and thus such rejection is withdrawn, but a new rejection is made herein over Fujimoto et al. (of record). Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 16-17 and 19-20 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Yang et al. (CN-101913952-A; published 15 December 2010; of record; citations herein to English machine translation made 09 January 2026; of record). Yang et al. discloses a fertilizer (i.e., an agrochemical composition) comprising large element fertilizer and bactericide and assistant (claim 1) wherein the large element fertilizer is potassium nitrate (claim 4) wherein the bactericide is hymexazole (i.e., hydroxyisoxazole; i.e., sole fungicidal ingredient) (claim 7) wherein the assistant/auxiliary agent may be polycarboxylate (i.e., a carboxylic acid type anionic surfactant) (claim 10; paragraph [0030]). Regarding the recitation of “consisting of”, although Yang et al. discloses inclusion of alginic acid, alginic acid is a binder, thickener, and bulking agent, which are not excluded from the claims (see, e.g., instant specification at paragraph [0078] of published application). Claim Rejections - 35 USC § 103 This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 15 and 18 is/are rejected under 35 U.S.C. 103 as being unpatentable over Fujimoto et al. (EP 0569210 A2; published 10 November 1993; of record). Fujimoto et al. discloses a soil fungicidal composition comprising 3-hydroxy-5- methylisoxazole or a salt thereof in admixture with an antimicrobial agent (claim 1) wherein 3-hydroxy-5-methylisoxazole is a fungicide (page 2 lines 1-3) wherein the composition may contain one or more surface active agents preferably non-ionic surface active agents to improve the properties of the compositions and help them to disperse, emulsify, spread, penetrate and bind (page 6 lines 47-52) such as polyoxyethylene alkyl ethers (page lines 53-54) wherein compositions thereof include a carrier and liquid formulations thereof may be aqueous (page 6 lines 18-23) wherein suitable liquid carriers include water (page 6 lines 36, 46) wherein an antimicrobial agent may be for example 1,5-pentanedial, 1,2-benzisothiazolin-3-one, and benzalkonium chloride (claims 8-9) wherein a liquid formulation may preferably contain 5-50% by weight active compound and 5-20% by weight emulsifying agent (page 7 lines 38-40). It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to follow the suggestions of Fujimoto et al. as discussed above and to make the soil fungicidal composition (i.e., agrochemical composition) of Fujimoto et al. as discussed above using 5-50 wt% 3-hydroxy-5- methylisoxazole (i.e., hydroxyisoxazole) fungicide active compound or a salt thereof and 5-20 wt% polyoxyethylene (i.e., POE) alkyl ether non-ionic surface active agent emulsifying agent (i.e., ether type nonionic surfactant) and water and antimicrobial agent of 1,5-pentanedial (i.e., glutaraldehyde), 1,2-benzisothiazolin-3-one, or benzalkonium chloride (i.e., preservatives and mildew-proofing agents, see, e.g., instant specification at paragraph [0083] of published application)) therein, with a reasonable expectation of success. Such concentrations result in a weight ratio of nonionic surfactant to hydroxyisoxazole of 5-20:5-50, or a weight ratio range of 5:50 to 20:5, or 0.1:1 to 4:1, which overlaps the claimed range of 0.02:1 to 0.5:1, and a prima facie case of obviousness exists where prior art and claimed ranges overlap per MPEP 2144.05(I). Allowable Subject Matter Claims 1, 5, 8-9, and 12-14 are allowed. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL B. PALLAY whose telephone number is (571)270-3473. The examiner can normally be reached Monday through Friday from 8:30 AM to 5:00 PM Eastern Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue Liu can be reached on (571)272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL B. PALLAY/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Show 12 earlier events
Dec 08, 2025
Response Filed
Jan 13, 2026
Final Rejection mailed — §102, §103
Apr 13, 2026
Response after Non-Final Action
May 11, 2026
Request for Continued Examination
May 13, 2026
Response after Non-Final Action
May 20, 2026
Non-Final Rejection mailed — §102, §103
Sep 17, 2026
Response Filed
Nov 02, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778888
METHOD AND SYSTEM FOR OTOTOPICAL DELIVERY USING NANOPARTICLES FOR EAR INFECTION DIAGNOSIS AND TREATMENT
3y 7m to grant Granted Nov 03, 2026
Patent 12780672
AMORPHOUS SILICA-BASED NANOPARTICLES AND METHODS OF MAKING THE SAME
3y 5m to grant Granted Nov 03, 2026
Patent 12778926
New Cooling Agents and Preparations Containing Them
3y 5m to grant Granted Nov 03, 2026
Patent 12778982
ANTIOXIDANT NUTRITIONAL SUPPLEMENT FOR IMMUNE SYSTEM SUPPORT
3y 4m to grant Granted Nov 03, 2026
Patent 12778907
USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME
3y 4m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
56%
Grant Probability
90%
With Interview (+33.6%)
3y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 746 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month